Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic

  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Castle Biosciences, Inc.

< Previous 1 2 3 4 Next >
Castle Biosciences to Present New Data Highlighting the Clinical Performance of DecisionDx®-Melanoma and MyPath® Melanoma at the American Society of Dermatopathology 61st Annual Meeting
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Real-World Evidence Confirms IDgenetix®-Guided Medication Management Significantly Improves Response and Remission Rates in Patients with Major Depressive Disorder
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences, Leading Skin Cancer Expert, Darrell Rigel, M.D., M.S., and IMPACT Melanoma Board Member to Ring Nasdaq Closing Bell on Sept. 27, 2023, to Raise Awareness of Melanoma
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Host Second Annual Castle Cares Charity Walk
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences’ Abstracts at Digestive Disease Week (DDW) Annual Meeting Selected as “Posters of Distinction” by the American Gastroenterological Association (AGA) Institute Council
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Opens New State-of-the-Art Laboratory in Pittsburgh
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences’ TissueCypher® Barrett's Esophagus Test Receives 2023 MedTech Breakthrough Award for Artificial Intelligence Innovation
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Reports First Quarter 2023 Results
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Study Demonstrates Use of DecisionDx®-Melanoma to Guide Treatment Decisions Resulted in Earlier Detection of Melanoma with Decreased Metastatic Tumor Burden Compared to Patients Without Surveillance Imaging Studies
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Collaborates with IMPACT Melanoma to Provide Free Sunscreen to Cyclists Participating in the Bike MS: Texas MS 150 2023 Cycling Event
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
DecisionDx®-Melanoma Provides Improved Risk Stratification Over American Joint Committee on Cancer (AJCC) Staging Alone in Stage I Melanoma Patients
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
TissueCypher® Test Results Can Increase the Likelihood of Appropriate Management Decisions for Barrett’s Esophagus Patients with Low-Grade Dysplasia
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Release First Quarter 2023 Financial Results and Host Conference Call on Wednesday, May 3
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Present at the 22nd Annual Needham Virtual Healthcare Conference
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Late-Breaking Data Presented at the 2023 AAD Annual Meeting Demonstrates Improved Accuracy of DecisionDx®-SCC in Predicting Metastatic Risk Over Traditional Staging Systems in Independent, Multi-Center Cohort Study
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Highlight Clinical Value of Its Skin Cancer Tests at the 2023 American Academy of Dermatology (AAD) Annual Meeting
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Recommendations by Expert Consensus Panel Relating to Risk-Stratification Tests and Tools for Use in Cutaneous Melanoma Have Been Adopted as an Official Policy Recommendation of the National Society for Cutaneous Medicine
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Reports Fourth Quarter and Full-Year 2022 Results
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences’ Chief Financial Officer Frank Stokes Selected Among the Top 25 CFOs of Houston for 2023 by Finance & Investing
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Data Presentation at 2023 Winter Clinical - Miami™ Highlights Use of DecisionDx®-Melanoma to Guide SLNB Surgery Decisions in Head and Neck Tumors
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Prospective, Multicenter Study Demonstrates That DecisionDx®-Melanoma Test Results Can Significantly Reduce the Number of Sentinel Lymph Node Biopsy (SLNB) Procedures Performed When Used Within the Context of Current Guidelines
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Release Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call on Tuesday, Feb. 28, 2023
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Earns a Top Workplaces USA Award for the Second Consecutive Year
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences’ Medical Director to Present at the Precision Medicine World Conference 2023
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Data Presentations at 2023 Winter Clinical Dermatology Conference - Hawaii® Support Clinical Value of Castle Biosciences’ Skin Cancer Test Portfolio
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2022 Results
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Receives Accreditation from the College of American Pathologists for its Pittsburgh Clinical Laboratory
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Research Published in Melanoma Management Finds that 99% of Patients with Uveal Melanoma Tested with DecisionDx®-UM Gain Value from the Results
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Presents New Data Demonstrating the Clinical Utility and Value of DecisionDx®-SCC in Moderately and Poorly Differentiated Cutaneous Squamous Cell Carcinoma Tumors
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.